Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial

Evidence of the effectiveness of prophylactic use of tranexamic acid (TXA) in thrombocytopenia is lacking. To determine whether TXA safely reduces bleeding incidence in patients undergoing treatment for hematologic malignancies, a randomized, double-blind clinical trial was conducted from June 2016...

Descripción completa

Detalles Bibliográficos
Autores principales: Gernsheimer, Terry B., Brown, Siobhan P., Triulzi, Darrell J., Key, Nigel S., El Kassar, Nahed, Herren, Heather, Poston, Jacqueline N., Boyiadzis, Michael, Reeves, Brandi N., Selukar, Subodh, Pagano, Monica B., Emerson, Scott, May, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479029/
https://www.ncbi.nlm.nih.gov/pubmed/35667085
http://dx.doi.org/10.1182/blood.2022016308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479029/
https://www.ncbi.nlm.nih.gov/pubmed/35667085
http://dx.doi.org/10.1182/blood.2022016308

Ejemplares similares